NovoCure Limited downgrade after TRIDENT OS miss; growth catalysts, raised 2026 guidance, and key risks ahead. Click for this ...

The decision was based on findings from the Phase III PANOVA-3 clinical trial.

Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.

(RTTNews) - Novocure (NVCR) announced the FDA approved new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Novocure ...

(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...

The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances ...

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Management issued guidance of $675 million to $705 million in net revenue for 2026, assuming Optune Gio net revenue growth in the low to mid-single digits and $15 million to $25 million in net revenue ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...